Mark J. Niciu, MD, PhD

Assistant Professor

Our clinical and translational research group seeks to better understand the pathophysiology and therapeutics of major mood and substance use disorders including their comorbidity. A major focus has been the identification, replication, and dissemination of biomarkers of treatment response to the glutamate modulator ketamine. As an example, our group and others have demonstrated that a history of an alcohol use disorder in an immediate family member is a positive predictor of antidepressant response to ketamine. Based on this observation, we are attempting to identify alcohol-sensitive biomarkers of antidepressant efficacy to ketamine and potentially other glutamate-based antidepressants. We take a multimodal approach to this work across several levels of analysis – genetics, stem-cell based models, neuroimaging, neurophysiology and psychology/behavioral testing – with the goal of translation to improve the lives of our patients and their families with these disabling disorders.

Recent publications

Research areas
  • Cellular and molecular neuroscience
  • Clinical neuroscience
  • Ion channels
  • Neurotransmitters
  • Receptors
  • Gene regulation
  • Addiction
  • Psychiatric disorders
  • Frontal cortex
  • Stress
  • Neuroimaging
  • Stem cells
  • Cell culturing
  • Pharmaco-MRI
Mark Niciu

W267 GH
United States

Phone Number


2310E-2 PBDB
United States

Phone Number